India's healthcare sector is a long-duration compounding story — rising per capita health spend, growing health insurance, medical tourism, and government Ayushman Bharat coverage are all tailwinds. Apollo Hospitals, Fortis, Max Healthcare, Dr Lal PathLabs, and Metropolis are the core listed plays.
9 companies in this theme — showing top 9 by market cap.
| Symbol | Company | Price | Mkt Cap | ROE | P/E |
|---|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd | ₹8,938 | ₹1,27,069 Cr | 16.1% | 84.60 |
| MAXHEALTH | Max Healthcare Institute Ltd | ₹1,081 | ₹1,05,232 Cr | 8.5% | 144.00 |
| FORTIS | Fortis Healthcare | ₹949.55 | ₹71,669 Cr | — | — |
| ASTERDM | Aster DM Healthcare Ltd | ₹799.5 | ₹68,570 Cr | 8.9% | 209.00 |
| NH | Narayana Hrudayalaya Ltd | ₹1,968 | ₹40,668 Cr | 22.5% | 75.70 |
| KIMS | Krishna Institute of Medical Sciences | ₹784.15 | ₹31,490 Cr | — | — |
| LALPATHLAB | Dr. Lal PathLabs | ₹1,699.65 | ₹28,370 Cr | — | — |
| RAINBOW | Rainbow Children's Medicare | ₹1,490.25 | ₹15,132 Cr | — | — |
| METROPOLIS | Metropolis Healthcare | ₹568.45 | ₹11,792 Cr | — | — |
Discover Fundamental And Valuation Research keeps this page inside the main discover cluster with sibling theme and workflow links.
Structural drivers: rising middle class with health awareness, government coverage expansion (Ayushman Bharat), aging population, and India's low healthcare spend vs GDP.
Hospitals are capex-heavy with 5–7 year EBITDA payback; diagnostics are capital-light with faster expansion. Both have merit depending on portfolio position.